Researchers have developed and preliminarily tested a composite score that simultaneously assesses the severity of asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) in patients with both ...

In this randomized controlled trial, among patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps, tezepelumab more effectively reduced nasal polyp size and sinonasal symptoms ...

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

Tezepelumab was linked to significantly reduced nasal polyp size and nasal congestion vs placebo in adults with severe CRSwNP.

Sanofi and Regeneron's fast-growing immunology drug Dupixent is on course for a third indication in Europe after being recommended for approval as a treatment for people with nasal polyps.

Bucks County specialty pharmaceutical company Optinose first started exploring mergers and licensing deals in early 2022.

Researchers at Columbus-based Ohio State University have designed and developed the world’s first noninvasive devices aimed ...